The eye warning the FDA added to Ozempic | The Receipts - Dataspheres AI

The eye warning the FDA added to Ozempic THE RECEIPTS The eye warning the FDA added to Ozempic November 10, 2026 What the FDA ordered on Monday What the FD...

The eye warning the FDA added to Ozempic THE RECEIPTS The eye warning the FDA added to Ozempic November 10, 2026 What the FDA ordered on Monday What the FDA ordered on Monday — Monday, November 9, 2026: the FDA published a Drug Safety Communication — It requires every GLP-1 drug sold in the United States to carry a new warning — The warning is about NAION, a rare eye condition that can end in permanent vision loss in one eye — It goes in the Warnings and Precautions section of the label, and nothing has been withdrawn The order, in numbers The order, in numbers 12 products named, from Byetta in 2005 to Foundayo 7 active ingredients across those products 126 randomised trials in the meta-analysis the FDA relied on 15 probable cases of the eye condition found in all of them What the condition is What the condition is — Non-arteritic anterior ischemic optic neuropathy, which doctors shorten to NAION — The FDA calls it a rare condition that can result in acute, painless, decreased vision in one eye — That includes permanent vision loss — It happens when blood flow drops to the front of the optic nerve Which drugs the order covers Which drugs the order covers 3 semaglutide products: Ozempic, Rybelsus and Wegovy 2 tirzepatide products: Mounjaro and Zepbound 3 liraglutide products: Victoza, Saxenda and Xultophy 4 more: Byetta, Trulicity, Soliqua and Foundayo The three things the FDA weighed The three things the FDA weighed The three things the FDA weighed The three things the FDA weighed The three things the FDA weighed What the trials found What the trials found — Across 126 trials: 6.4 events per 100,000 person-years on a GLP-1 drug, against 3.8 on a comparator — In raw counts that is ten cases against five, with none on other glucose-lowering drugs — 134,253 patients took part and 288,879 person-years of treatment were covered — Numbers this small cannot separate a real effect from chance on their own, which is why the FDA also read its real-world data Europe said it seventeen months ago Europe said it seventeen months ago — On June 6, 2025 the European Medicines Agency’s safety committee finished its own review — It concluded NAION is a very rare side effect of semaglutide, meaning up to 1 in 10,000 people — It put the risk at roughly twice that of people not taking the medicine — In plain terms: about one extra case per 10,000 person-years of treatment Why it reaches so many people Why it reaches so many people 12% of American adults were taking a GLP-1 drug when KFF asked 18% said they had taken one at some point 1,350 adults in the nationally representative sample Oct 27 - Nov 2 the dates the 2025 survey was in the field What the makers said “The data do not establish a cause-and-effect relationship.” — Novo Nordisk, which makes Ozempic, Wegovy and Rybelsus, in a statement to Reuters on November 9, 2026, adding that it remains confident in the benefit-risk profile of its medicines. Eli Lilly, which makes Mounjaro and Zepbound, said the FDA communication applies to all medicines with GLP-1 receptor agonist activity and pointed to no findings specific to its own What the FDA tells patients to do What the FDA tells patients to do — Sudden, painless loss of vision in one eye means contacting a health care professional right away — So does a missing patch of vision, distorted colour, or a drop in central sharpness — Prescribers are told to refer those patients promptly to an ophthalmologist — The FDA does not tell anyone to stop taking these drugs; it says to weigh continuing against the risk Rare is not the same as nothing Rare is not the same as nothing Fifteen cases across 126 trials is a small signal, and the FDA says so: it calls the risk potential and the mechanism unclear. What changed on November 9 is not the science but the paperwork - every one of these twelve products now has to print the one symptom that means calling a doctor the same day. This is information taken from the regulator’s own document, not medical advice. Stay up to date with Dataspheres AI Stay up to date with Dataspheres AI Sign up and get the Dataspheres AI Weekly: the week's key stories and what to watch next. dataspheres.ai/signup Scan to sign up